Predictors of family impact of juvenile localized scleroderma. Issue 5 (14th July 2021)

• Record Type: Journal Article
• Authors: Milovanova, Katia; Adly, Merna; Lethebe, Brendan C.; Stevenson, Rebeka; Prajapati, Vimal H.; Luca, Nadia J. C.
• Is Part Of: Pediatric dermatology. Volume 38:Issue 5(2021)
• Page Start: 1137
• Page End: 1142
• Publication Date: 2021-07-14
• Subjects: child -- family -- quality of life -- rheumatology -- dermatology -- scleroderma -- localized; Pediatric dermatology -- Periodicals; Children -- Diseases -- Periodicals; 618.925
• DOI: 10.1111/pde.14683
• Languages: English
• ISSNs: 0736-8046

Abstract

Abstract: Objective: To measure the impact juvenile localized scleroderma (jLS) has on family quality of life and to identify predictors of family impact in this population which may inform the development of tailored resources to enhance family functioning for patients with jLS. Methods: A retrospective cohort study of pediatric patients with jLS and their families was conducted. Five questionnaires were administered at each visit: Pediatric Quality of Life Inventory Family Impact Module (PedsQL‐FIM), PedsQL 4.0 Generic Core Scales (PedsQL‐Generic), PedsQL Rheumatology Module (PedsQL‐RM), Child Health Assessment Questionnaire (CHAQ), and Children's Dermatology Life Quality Index (CDLQI). Linear mixed models with random intercepts for each patient were used to find relationships between family impact scores and clinically relevant variables over time. Variables of interest included disease activity status, methotrexate use, jLS distribution, and scores for PedsQL‐Generic and PedsQL‐RM. Results: The median baseline PedsQL‐FIM total score was 80.9 (IQR = 76.6‐97.4). Adjusting for age and sex, the most significant predictors of family impact were PedsQL‐Generic scores and four of five PedsQL‐RM dimensions (all P < .001); methotrexate use had borderline significance ( P = .06). Family impact increased more significantly over time in older patients. In multivariable modeling, PedsQL‐Generic total score and jLS "other" distribution were significant for predicting an increased PedsQL‐FIM score ( P = .003 and P = .03, respectively). Conclusions: JLS has a moderate family impact. Family impact is predicted by patients' general and disease‐specific health‐related quality of life (HRQL) and their jLS subtype. There is a trend toward increased family impact with methotrexate treatment. This study emphasizes the importance of family‐centered care in jLS.